Science Links Japan | Treatment of nocturnal periodic hypoxemia with safrazine hydrochrolide in a patient with Duchenne muscular dystrophy under nasal intermittent positive pressure ventilation.

Treatment of nocturnal periodic hypoxemia with safrazine hydrochrolide in a patient with Duchenne muscular dystrophy under nasal intermittent positive pressure ventilation.

Accession number;99A0183165

Title;Treatment of nocturnal periodic hypoxemia with safrazine hydrochrolide in a patient with Duchenne muscular dystrophy under nasal intermittent positive pressure ventilation.

Author; OGATA KATSUHISA (National Sanatorium Shimo-Shizu Hospital) NAKAYAMA TAKAHIRO (National Sanatorium Shimo-Shizu Hospital) KAWAI MITSURU (National Sanatorium Shimo-Shizu Hospital)

Journal Title;Clinical Neurology

Journal Code:Z0689A

ISSN:0009-918X

VOL.38;NO.8;PAGE.776-778(1998)

Figure&Table&Reference;FIG.2, REF.6

Pub. Country;Japan

Language;Japanese

Abstract;Nocturnal periodic hypoxemia occurring in a 25-year-old Duchenne muscular dystrophy patient under NIPPV control was successfully treated with monoamine oxydase inhibitor(MAOI), safrazine hydrochrolide. Five mg of safrazine hydrochrolide was administered before sleep, and the periodic hypoxemia disappeared within 14 days. The effect lasted almost seven months without notable side effect. MAOI may be effective for nocturnal hypoventilation through supression of REM sleep as in the case of tricyclic antidepressants. The effect of tricyclic antidepressants appears immediately. However, it usually fades away within forty days. Safrazine hydro-chrolide was effective obviously longer than tricyclic antidepressants. Consequently MAOI may be a hopeful candidate of medication for a treatment of nocturnal periodic hypoxemia in Duchenne muscular dystrophy. (author abst.)

Related Articles;